A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Authors

Margaret Phillips

Published

July 15, 2015

Abstract

The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aaa6645

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Authors

Margaret Phillips

Published

July 15, 2015

Abstract

The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans.

Supporters

Support the authors with ResearchCoin

Journal

Science Translational Medicine

Topics

DOI

10.1126/scitranslmed.aaa6645

Paper

Paper

Paper

Paper

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Abstract

Supporters

Journal

Topics

DOI

A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

Abstract

Supporters

Journal

Topics

DOI